NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Major U.S. markets closed up on Monday, with the Dow Jones posting its 8th consecutive daily gain, as trade tensions between U.S. and China eased. The Dow Jones Industrial Average gained 0.27 percent to close at 24,899.41, while the S&P 500 Index increased 0.09 percent to close at 2,730.13. The Nasdaq Composite Index climbed 0.11 percent to close at 7,411.32.

"We're getting a bump higher on this trade news, since it seems like Trump is backing off his rhetoric with China. He came out very aggressively, but now he?s walking that back, which is encouraging," said Paul Nolte, portfolio manager at Kingsview Asset Management.

"Now, I don't think the concerns are fully out of the market. We're still seeing higher interest rates and valuations are still at the high end of their historical range," Nolte added.

RDI Initiates Coverage on:

OPKO Health, Inc.
https://rdinvesting.com/news/?ticker=OPK

Halozyme Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=HALO

OPKO Health's stock jumped 5.75% Monday, to close the day at $4.78. The stock recorded a trading volume of 8,231,819 shares, which was above its three months average volume of 4,679,677 shares. In the last year, OPKO Health's shares have traded in a range of 2.66 - 7.25. The share price has gained 79.7% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.22 is below its 200-day moving average of $4.29. Shares of OPKO Health have gained roughly 59.87 percent in the past month and are down 2.45 percent year-to-date.

Access RDI's OPKO Health, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OPK

On Monday, shares of Halozyme Therapeutics recorded a trading volume of 1,187,296 shares, which was above the three months average volume of 920,147 shares. The stock ended the day 5.55% higher at $19.87. The share price has fallen 7.5% from its 52 week high with a 52 week trading range of 11.41 - 21.48. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $19.34 is above its 200-day moving average of $19.18. Shares of the company are trading at a Price to Earnings ratio of 44.16. Shares of Halozyme Therapeutics have gained roughly 2.58 percent in the past month and are down 1.92 percent year-to-date.

Access RDI's Halozyme Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HALO

Our Actionable Research on OPKO Health, Inc. (NASDAQ:OPK) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com